Keywords
How to Cite
Abstract
Sars-Cov-2, known as COVID-19, is a virus belonging to coronavirus family, whose characteristic
is the development of respiratory diseases, mainly pneumonia, with a high risk of progression to acute respiratory distress syndrome, which in turn is related to high morbidity and mortality rates that vary from case to case. Although a specific management scheme is not available, the use of convalescent plasma has been proposed as a therapeutic alternative, so studies are currently being carried out to evaluate its efficacy, although there are preliminary reports of published studies with encouraging results with low risk and possible benefits of this therapy. We present our case experience regarding the use of convalescent plasma in a 24 years old patient diagnosed with COVID-19 pneumonia at our institution.
References
2. W.H.O. (2020, 07,19). Situation reports. https://www. who.int /emergencies/- diseases/novel-coronavirus-2019/situation reports.
3. Mair-Jenkins J, Saavedra-Campos M, Baillie JK et al.The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis. J Infect Dis. 2015; 211(1): 80-90.
4. Duan K, Liu B, Li C et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 2020; 117(17): 9490-6.
5. Gárgano C, Piaz A. Fiebre hemorrágica Argentina. Conflictos y desafíos para la ciencia en el ámbito rural. Asclepio. 2017; 69: 178-84.
6. Doremalen N, Munster V et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARSCoV-1. N Engl J Med. 2020; 382:1564-7.
7. Hoffmann M, Kleine-Weber H, Schroederet S et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181: 271-80.
8. Ye Q, Wang B, Mao J et al. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19. J Infect. 2020; 80(6): 607-13.
9. Ackermann M, Verleden SE, Kuehnel M et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020; 383: 120-8.
10. Lauer SA, Grantz KH, Bi Q et al. The incubation period of coronavirus disease 2019 (COVID-19) from
publicly reported confirmed cases: estimation and application. Ann Intern Med 2020 Ann Intern Med. 2020; 172(9): 577-82.
11. Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,
China. Lancet. 2020;395(10223):497-506.
12. Cao B, Wang Y, Wen D et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
N Engl J Med. 2020; 382: 1787-99.
13. Beigel JH, Tomashek KM, Dodd LE et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. N Engl J Med. 2020; NEJMoa2007764.
14. Horby P, Lim HS, Embersonet JR et al. RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020;10.1056/NEJMoa2021436.
15. Li l, Zhang W, Hu Y et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19. A Randomized Clinical Trial. JAMA. 2020. e2010044.doi: 10.1001/jama.2020.10044.
16. Joyner M, Wright RS, Fairweather D et al. Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients. J Clin Invest. 2020. https://doi.org/10.1172/JCI140200.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar